Erratum to: Mortality of patients with multiple sclerosis: a cohort study in UK primary care

S. S. Jick · L. Li · G. J. Falcone ·
Z. P. Vassilev · M.-A. Wallander

Published online: 3 July 2014
© Springer-Verlag Berlin Heidelberg 2014

Erratum to: J Neurol
DOI 10.1007/s00415-014-7370-3

Unfortunately, the online published article has errors in footnote of Tables 1, 2 and 3. The correct tables are given in the following pages.

The online version of the original article can be found under
doi:[10.1007/s00415-014-7370-3](https://doi.org/10.1007/s00415-014-7370-3).

S. S. Jick (✉) · L. Li
Boston Collaborative Drug Surveillance Program,
Boston University School of Public Health,
11 Muzzey Street, Lexington, MA 02421, USA
e-mail: sjick@bu.edu

G. J. Falcone
Department of Neurology, Massachusetts General Hospital,
Boston, MA, USA

G. J. Falcone
Department of Epidemiology, Harvard School of Public Health,
Boston, MA, USA

Z. P. Vassilev
Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA

M.-A. Wallander
Department of Public Health and Caring Science, Uppsala
University, Uppsala, Sweden

Table 1 Basic characteristics of MS cases and matched referent subjects at cohort entry, overall and stratified by type of MS

Characteristic	MS cases <i>N</i> = 1,822 [<i>n</i> (%)]	Referents <i>N</i> = 18,211 [<i>n</i> (%)]	RRMS ^a <i>N</i> = 769 [<i>n</i> (%)]	Referents <i>N</i> = 7,690 [<i>n</i> (%)]	PPMS <i>N</i> = 125 [<i>n</i> (%)]	Referents <i>N</i> = 1,250 [<i>n</i> (%)]
Mean age (years) at cohort entry (index date; SD)	42.08 (11.79)	42.0 (11.72)	40.01 (11.14)	39.94 (11.15)	49.98 (10.43)	49.92 (10.39)
Sex						
Males	481 (26.40)	4,801 (26.36)	193 (25.10)	1,930 (25.10)	53 (42.40)	530 (42.40)
Females	1,341 (73.60)	13,410 (73.64)	576 (74.90)	5,760 (74.90)	72 (57.60)	720 (57.60)
Smoking status						
Current ^{*,†}	569 (31.23)	4,363 (23.96)	226 (29.39)	1,902 (24.73)	40 (32.00)	289 (23.12)
Former	239 (13.12)	2,390 (13.12)	101 (13.13)	963 (12.52)	23 (18.40)	199 (15.92)
Never	777 (42.65)	8,921 (48.99)	349 (45.38)	3,807 (49.51)	50 (40.00)	595 (47.60)
Unknown	237 (13.01)	2,537 (13.93)	93 (12.09)	1,018 (13.24)	12 (9.60)	167 (13.36)
BMI (kg/m ²)						
<18.5	46 (2.52)	379 (2.08)	17 (2.21)	179 (2.33)	2 (1.60)	18 (1.44)
18.5–24.99	706 (38.75)	6,948 (38.15)	301 (39.14)	2,980 (38.75)	46 (36.80)	408 (32.64)
25.0–29.99	426 (23.38)	4,100 (22.51)	187 (24.32)	1,676 (21.79)	39 (31.20)	339 (27.12)
≥30	248 (13.61)	2,406 (13.21)	112 (14.56)	993 (12.91)	12 (9.60)	198 (15.84)
Unknown	396 (21.73)	4,378 (24.04)	152 (19.77)	1,862 (24.21)	26 (20.80)	287 (22.96)
Alcohol abuse [†]	25 (1.37)	370 (2.03)	3 (0.39)	133 (1.73)	5 (4.0)	50 (4.0)
Mean length of recorded medical history (years; SD)						
Before index date	7.86 (4.44)	7.97 (4.43)	7.93 (4.50)	8.03 (4.49)	8.83 (4.51)	9.02 (4.52)
Follow-up after index date [†]	7.85 (4.50)	7.95 (4.49)	8.95 (4.33)	8.18 (4.40)	8.15 (4.32)	8.15 (4.08)

Type of MS was determined from original clinical records for 894 patients

BMI body mass index, *MS* multiple sclerosis, *PPMS* primary progressive MS, *RRMS* relapsing-remitting MS, *SD* standard deviation

* $p < 0.05$ for comparison between patients with MS and matched referent subjects (for all MS patients)

† $p < 0.05$ for comparison between patients with RRMS and matched referent subjects

^a Includes 64 patients with secondary progressive MS

Table 2 Comorbidities of MS cases and matched referent subjects at cohort entry, overall and stratified by type of MS

Characteristic	MS cases <i>N</i> = 1,822 [<i>n</i> (%)]	Referents <i>N</i> = 18,211 [<i>n</i> (%)]	RRMS ^a cases <i>N</i> = 769 [<i>n</i> (%)]	Referents <i>N</i> = 7,690 [<i>n</i> (%)]	PPMS cases <i>N</i> = 125 [<i>n</i> (%)]	Referents <i>N</i> = 1,250 [<i>n</i> (%)]
Chronic comorbidities ^b						
COPD and asthma	302 (16.58)	2,890 (15.87)	117 (15.21)	1,245 (16.19)	18 (14.40)	197 (15.76)
Depression ^{*,†,§}	508 (27.88)	3,677 (20.19)	188 (24.45)	1,529 (19.88)	45 (36.00)	238 (19.04)
Diabetes	35 (1.92)	390 (2.14)	13 (1.69)	141 (1.83)	3 (2.40)	44 (3.52)
Hypertension	137 (7.52)	1,544 (8.48)	47 (6.11)	538 (7.00)	13 (10.40)	179 (14.32)
Heart disease	34 (1.87)	439 (2.41)	8 (1.04)	119 (1.55)	4 (3.20)	64 (5.12)
Cancer	50 (2.74)	558 (3.06)	15 (1.95)	223 (2.90)	5 (4.00)	50 (4.00)
Acute comorbidities ^c						
Acute respiratory infection [§]	252 (13.83)	2,673 (14.68)	113 (14.69)	1,143 (14.86)	9 (7.20)	171 (13.68)
Pneumonia and influenza	18 (0.99)	169 (0.93)	11 (1.43)	70 (0.91)	1 (0.80)	14 (1.12)
Urinary tract infection [*]	99 (5.43)	683 (3.75)	36 (4.68)	284 (3.69)	8 (6.40)	41 (3.28)
Skin infection	164 (9.00)	1,566 (8.60)	68 (8.84)	652 (8.48)	5 (4.00)	96 (7.68)
Eye or Ear infection	4 (0.22)	33 (0.18)	3 (0.39)	15 (0.20)	0 (–)	0 (–)
Other infection ^{*,†}	149 (8.18)	1,256 (6.90)	69 (8.97)	533 (6.93)	5 (4.00)	73 (5.84)
Dyspepsia	35 (1.92)	282 (1.55)	11 (1.43)	120 (1.56)	2 (1.60)	23 (1.84)
Charlson Comorbidity Index at cohort entry						
Low (0)	1,393 (76.45)	14,192 (77.93)	615 (79.97)	6,048 (78.65)	96 (76.80)	931 (74.48)
Medium (1–2)	405 (22.23)	3,822 (20.99)	147 (19.12)	1,574 (20.47)	26 (20.80)	296 (23.68)
High (>2)	24 (1.32)	197 (1.08)	7 (0.91)	68 (0.88)	3 (2.40)	23 (1.84)

Type of MS was determined from original clinical records for 894 patients

COPD chronic obstructive pulmonary disorder, *MS* multiple sclerosis, *PPMS* primary progressive MS, *RRMS* relapsing-remitting MS

^{*} $p < 0.05$ for comparison between patients with MS and matched referent subjects (for all MS patients)

[†] $p < 0.05$ for comparison between patients with RRMS and matched referent subjects

[§] $p < 0.05$ for comparison between patients with PPMS and matched referent subjects

^a Includes 64 patients with secondary progressive MS

^b Ever before, or at cohort entry

^c During the year before, or at index date

Table 3 Comedications of MS cases and matched referent subjects at cohort entry, overall and stratified by type of MS

Characteristic	All MS cases <i>N</i> = 1,822 [<i>n</i> (%)]	Referents <i>N</i> = 18,211 [<i>n</i> (%)]	RRMS ^a cases <i>N</i> = 769 [<i>n</i> (%)]	Referents <i>N</i> = 7,690 [<i>n</i> (%)]	PPMS cases <i>N</i> = 125 [<i>n</i> (%)]	Referents <i>N</i> = 1,250 [<i>n</i> (%)]
Comedications (at cohort entry [index date] or within the 6 months before)						
Systemic glucocorticoids ^{*,†}	180 (9.88)	713 (3.92)	69 (8.97)	288 (3.75)	8 (6.40)	52 (4.16)
Antidepressants ^{*,†,§}	380 (20.86)	1,582 (8.69)	132 (17.17)	662 (8.61)	28 (22.40)	102 (8.16)
Anticonvulsants ^{*,†,§}	122 (6.70)	225 (1.24)	40 (5.20)	88 (1.14)	11 (8.80)	25 (2.00)
Antidiabetics	24 (1.32)	283 (1.55)	12 (1.56)	112 (1.46)	0 (–)	30 (2.40)
Opioids ^{*,†,§}	345 (18.94)	1,585 (8.70)	122 (15.86)	621 (8.08)	23 (18.40)	133 (10.64)
NSAIDs ^{*,†}	316 (17.34)	1,806 (9.92)	122 (15.86)	710 (9.23)	21 (16.80)	152 (12.16)
Statins [*]	61 (3.35)	447 (2.45)	20 (2.60)	137 (1.78)	4 (3.20)	75 (6.00)
Antibiotics ^{*,†}	403 (22.12)	3,598 (19.76)	179 (23.28)	1,546 (20.10)	16 (12.80)	227 (18.16)
Muscle relaxants ^{*,†,§}	173 (9.50)	399 (2.19)	50 (6.50)	153 (1.99)	20 (16.00)	37 (2.96)
Antipsychotics ^{*,†}	122 (6.70)	387 (2.13)	54 (7.02)	160 (2.08)	5 (4.00)	20 (1.60)
Anti-Parkinson drugs ^{*,†,§}	23 (1.26)	54 (0.30)	8 (1.04)	17 (0.22)	3 (2.40)	4 (0.32)
PPIs [*]	83 (4.56)	657 (3.61)	24 (3.12)	243 (3.16)	6 (4.80)	68 (5.44)

Type of MS was determined from original clinical records for 894 patients

MS multiple sclerosis, NSAIDs non-steroidal anti-inflammatory drugs, PPMS primary progressive MS, PPIs proton pump inhibitors, RRMS relapsing-remitting MS

* $p < 0.05$ for comparison between patients with MS and matched referent subjects (for all MS patients)

† $p < 0.05$ for comparison between patients with RRMS and matched referent subjects

§ $p < 0.05$ for comparison between patients with PPMS and matched referent subjects

^a Includes 64 patients with secondary progressive MS